There have been very few studies investigating BRAF V600E mutation status and odds of objective imaging response to ICI (37), and to our knowledge we are among the first to report this association in a real-world cohort of patients with advanced melanoma receiving first-line ICI therapy. This evidence concerns the gene BRAF and melanoma.